Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival

Vanessa M. Hayes, Gianluca Severi, Melissa C. Southey, Emma J.D. Padilla, Dallas R. English, John L. Hopper, Graham G. Giles, Robert L. Sutherland

Research output: Contribution to journalArticleResearchpeer-review

27 Citations (Scopus)


Macrophage inhibitory cytokine-1 (MIC-1), a member of the transforming growth factor-β superfamily, is important in regulating inflammation. Inflammation of the prostate has been suggested to favor tumor development. A recent study (JNCI 2004, 96:1248-1254) found marginal evidence of an association between the presence of the mature MIC-1 protein nonsynonymous polymorphism H6D C-to-G (rs1058587) with reduced prostate cancer risk [odds ratio, 0.83; 95% confidence interval (95% CI), 0.69-0.99]. We tested this in a population-based study of 819 cases and 731 controls from Australia and found a similar, yet not significant, odds ratio of 0.85 (95% CI, 0.7-1.04; P = 0.11). We also tested the potential association between the H6D variant and disease-specific survival in 640 cases followed-up for an average of 8.2 years. We found that cases carrying the H6D G allele had an increased risk of death from prostate cancer than cases carrying two copies of the C allele (hazard ratio, 1.72; 95% CI, 1.06-2.78; P = 0.03). Our data suggest that the H6D variant in MIC-1 might play a role in prostate cancer, but it is difficult to explain how a variant can be associated with lower risk of developing prostate cancer but more aggressive growth if cancer develops.

Original languageEnglish
Pages (from-to)1223-1225
Number of pages3
JournalCancer Epidemiology, Biomarkers & Prevention
Issue number6
Publication statusPublished - 1 Jun 2006
Externally publishedYes

Cite this